Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Revolution Medicines (RVMDW) Equity Average (2019 - 2025)

Historic Equity Average for Revolution Medicines (RVMDW) over the last 7 years, with Q3 2025 value amounting to $1.7 billion.

  • Revolution Medicines' Equity Average rose 870.04% to $1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year increase of 870.04%. This contributed to the annual value of $2.0 billion for FY2024, which is 6291.42% up from last year.
  • Latest data reveals that Revolution Medicines reported Equity Average of $1.7 billion as of Q3 2025, which was up 870.04% from $2.0 billion recorded in Q2 2025.
  • Over the past 5 years, Revolution Medicines' Equity Average peaked at $2.2 billion during Q1 2025, and registered a low of $524.9 million during Q2 2022.
  • In the last 5 years, Revolution Medicines' Equity Average had a median value of $884.1 million in 2023 and averaged $1.1 billion.
  • Per our database at Business Quant, Revolution Medicines' Equity Average skyrocketed by 41441.34% in 2021 and then tumbled by 2541.6% in 2022.
  • Revolution Medicines' Equity Average (Quarter) stood at $620.4 million in 2021, then rose by 10.14% to $683.3 million in 2022, then soared by 94.91% to $1.3 billion in 2023, then surged by 43.84% to $1.9 billion in 2024, then fell by 9.64% to $1.7 billion in 2025.
  • Its Equity Average was $1.7 billion in Q3 2025, compared to $2.0 billion in Q2 2025 and $2.2 billion in Q1 2025.